[go: up one dir, main page]

EE200000289A - Asendatud 4-amino-tiasool-2-üüli ühendid kui tsükliinisõltuvusega kinaaside inhibiitorid - Google Patents

Asendatud 4-amino-tiasool-2-üüli ühendid kui tsükliinisõltuvusega kinaaside inhibiitorid

Info

Publication number
EE200000289A
EE200000289A EEP200000289A EEP200000289A EE200000289A EE 200000289 A EE200000289 A EE 200000289A EE P200000289 A EEP200000289 A EE P200000289A EE P200000289 A EEP200000289 A EE P200000289A EE 200000289 A EE200000289 A EE 200000289A
Authority
EE
Estonia
Prior art keywords
aminothiazol
cyclin
inhibitors
substituted
compounds
Prior art date
Application number
EEP200000289A
Other languages
English (en)
Estonian (et)
Inventor
Song Chu Shao
K. M. Chong Wesley
K. Duvadie Rohit
Li Lin
Xiao Wei
Yang Yi
Original Assignee
Agouron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agouron Pharmaceuticals, Inc. filed Critical Agouron Pharmaceuticals, Inc.
Publication of EE200000289A publication Critical patent/EE200000289A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
EEP200000289A 1997-10-27 1998-10-27 Asendatud 4-amino-tiasool-2-üüli ühendid kui tsükliinisõltuvusega kinaaside inhibiitorid EE200000289A (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6363497P 1997-10-27 1997-10-27
US6366697P 1997-10-28 1997-10-28
PCT/US1998/022809 WO1999021845A2 (en) 1997-10-27 1998-10-27 4-aminothiazole derivatives, their preparation and their use as inhibitors of cyclin-dependent kinases

Publications (1)

Publication Number Publication Date
EE200000289A true EE200000289A (et) 2001-06-15

Family

ID=26743609

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000289A EE200000289A (et) 1997-10-27 1998-10-27 Asendatud 4-amino-tiasool-2-üüli ühendid kui tsükliinisõltuvusega kinaaside inhibiitorid

Country Status (34)

Country Link
US (2) US6569878B1 (xx)
EP (1) EP1056732B1 (xx)
JP (1) JP2004500304A (xx)
KR (1) KR20010082501A (xx)
CN (1) CN1158269C (xx)
AP (1) AP1445A (xx)
AT (2) ATE332896T1 (xx)
AU (1) AU738792B2 (xx)
BG (1) BG64195B1 (xx)
BR (1) BR9815200A (xx)
CA (1) CA2306082A1 (xx)
DE (2) DE69835241T2 (xx)
EA (1) EA003527B1 (xx)
EE (1) EE200000289A (xx)
ES (2) ES2256968T3 (xx)
GE (1) GEP20032896B (xx)
HR (1) HRP20000222A2 (xx)
HU (1) HUP0004512A3 (xx)
ID (1) ID24372A (xx)
IL (1) IL135574A0 (xx)
IS (1) IS5462A (xx)
LT (1) LT4855B (xx)
LV (1) LV12592B (xx)
NO (1) NO20001955L (xx)
NZ (1) NZ503788A (xx)
OA (1) OA11352A (xx)
PL (1) PL342447A1 (xx)
RO (1) RO119463B1 (xx)
SI (1) SI20324A (xx)
SK (1) SK5212000A3 (xx)
TR (1) TR200001081T2 (xx)
UA (1) UA66810C2 (xx)
WO (1) WO1999021845A2 (xx)
YU (1) YU22400A (xx)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK5212000A3 (en) * 1997-10-27 2001-04-09 Agouron Pharmaceuticals Inc Ag 4-aminothiazole derivatives, their preparation and their use as inhibitors of cyclin-dependent kinases
UA60365C2 (uk) 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
BR9914018A (pt) * 1998-09-22 2001-07-03 Yamanouchi Pharmaceuticals Co Derivado de cianofenila
US6414156B2 (en) 1998-10-21 2002-07-02 Bristol-Myers Squibb Company Process for preparing azacycloalkanoylaminothiazoles
US6214852B1 (en) 1998-10-21 2001-04-10 Bristol-Myers Squibb Company N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
EP3222619A1 (en) 1999-04-15 2017-09-27 Bristol-Myers Squibb Holdings Ireland Cyclic protein tyrosine kinase inhibitors
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
UA71971C2 (en) 1999-06-04 2005-01-17 Agoron Pharmaceuticals Inc Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
PE20010306A1 (es) * 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
US7141581B2 (en) 1999-07-02 2006-11-28 Agouron Pharmaceuticals, Inc. Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
US6114365A (en) * 1999-08-12 2000-09-05 Pharmacia & Upjohn S.P.A. Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents
US6392053B2 (en) 1999-12-15 2002-05-21 Bristol-Myers Squibb Company Process for preparing arylacetylaminothiazoles
US6515004B1 (en) 1999-12-15 2003-02-04 Bristol-Myers Squibb Company N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
HN2001000008A (es) 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
AU2001230026A1 (en) * 2000-02-04 2001-08-14 Novo-Nordisk A/S 2,4-diaminothiazole derivatives
CA2398446A1 (en) 2000-04-18 2001-10-25 Agouron Pharmaceuticals, Inc. Pyrazoles for inhibiting protein kinases
KR100423899B1 (ko) 2000-05-10 2004-03-24 주식회사 엘지생명과학 세포 증식 억제제로 유용한 1,1-디옥소이소티아졸리딘을갖는 인다졸
BR0113139A (pt) * 2000-08-09 2003-06-24 Agouron Pharma Compostos, seus sais, formas multiméricas, pró-drogas ou metabólitos, composições farmacêuticas, método de tratamento de uma doença ou disfunção mediana através da inibição de cdk4 ou um complexo de cdk4/ciclina, método de tratamento de condição doentia em mamìferos mediada pela atividade de proteìna cinase e método de modulação ou inibição da atividade de um receptor de proteìna cinase
AU2001279090A1 (en) 2000-08-18 2002-03-04 Agouron Pharmaceuticals, Inc. Heterocyclic-hydroxyimino-fluorenes and their use for inhibiting protein kinases
EP1712550A3 (en) * 2000-12-22 2009-07-15 Ortho-McNeil Pharmaceutical, Inc. Substituted triazole diamine derivatives as kinase inhibitors
PL363316A1 (en) * 2000-12-22 2004-11-15 Ortho Mc Neil Pharmaceutical, Inc. Substituted triazole diamine derivatives as kinase inhibitors
US6756374B2 (en) 2001-01-22 2004-06-29 Hoffmann-La Roche Inc. Diaminothiazoles having antiproliferative activity
CA2450562A1 (en) * 2001-06-22 2003-01-03 Merck & Co., Inc. Tyrosine kinase inhibitors
HN2002000156A (es) * 2001-07-06 2003-11-27 Inc Agouron Pharmaceuticals Derivados de benzamida tiazol y composiciones farmaceuticas para inhibir la proliferacion de celulas y metodos para su utilización.
EP1724270A3 (en) 2001-07-19 2007-01-03 Pfizer Italia S.r.l. Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents
MXPA04000906A (es) * 2001-08-03 2004-11-22 Novo Nordisk As Nuevos derivados de 2,4-diaminotiazol.
MEP46108A (en) 2002-01-22 2011-02-10 Warner Lambert Co 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d]PYRIMIDIN-7-ONES
US6818663B2 (en) * 2002-05-17 2004-11-16 Hoffmann-La Roches Diaminothiazoles
UA77303C2 (en) 2002-06-14 2006-11-15 Pfizer Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
US6872724B2 (en) 2002-07-24 2005-03-29 Merck & Co., Inc. Polymorphs with tyrosine kinase activity
BR0312798A (pt) 2002-07-25 2005-05-03 Pfizer Prod Inc Derivados de isotiazol úteis como agentes anticancerìgenos
JP2006502131A (ja) * 2002-08-07 2006-01-19 エフ．ホフマン−ラ　ロシュ　アーゲー チアゾール誘導体
US7157455B2 (en) 2003-02-10 2007-01-02 Hoffmann-La Roche Inc. 4-Aminopyrimidine-5-one derivatives
BRPI0407456A (pt) * 2003-02-12 2006-01-31 Pfizer Derivados antiproliferativos de 2-(sulfo-fenil)-aminotiazole e composições farmacêuticas, e métodos para o seu uso
EP1597256A1 (en) * 2003-02-21 2005-11-23 Pfizer Inc. N-heterocyclyl-substituted amino-thiazole derivatives as protein kinase inhibitors
PL1635824T3 (pl) 2003-06-03 2010-01-29 Novartis Ag 5-Członowe heterocykliczne inhibitory P-38
BRPI0411825B8 (pt) 2003-06-26 2021-05-25 Novartis Ag inibidores de p38 quinase a base de heterociclo de 5 elementos, seus processos de preparação e seus usos, bem como composição farmacêutica
TWI372050B (en) 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
AU2004261459B2 (en) 2003-07-22 2008-06-26 Astex Therapeutics Limited 3, 4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators
CA2532236C (en) 2003-07-29 2011-08-23 Novo Nordisk A/S Pyridazinyl- piperazines and their use as histamine h3 receptor ligands
WO2005047504A1 (en) * 2003-11-07 2005-05-26 The Board Of Trustees Of The University Of Illinois Induction of cellular senescence by cdk4 disruption for tumor suppression and regression
US20050171182A1 (en) * 2003-12-11 2005-08-04 Roger Briesewitz Methods and compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
EP1550372A1 (en) * 2003-12-24 2005-07-06 Bayer CropScience GmbH Plant growth regulation
CN1934107A (zh) * 2004-01-30 2007-03-21 Ab科学公司 作为酪氨酸激酶抑制剂的2－(3－取代芳基)氨基－4－芳基－噻唑
US7179827B2 (en) 2004-03-31 2007-02-20 Lexicon Genetics Incorporated Thiazoles and methods of their use
US7211576B2 (en) * 2004-04-20 2007-05-01 Hoffmann-La Roche Inc. Diaminothiazoles
JP2008503446A (ja) 2004-05-06 2008-02-07 プレキシコン，インコーポレーテッド Ｐｄｅ４ｂ阻害剤及びその使用
US7405220B2 (en) 2004-06-09 2008-07-29 Hoffmann-La Roche Inc. Pyrazolopyrimidines
US7423053B2 (en) * 2004-07-15 2008-09-09 Hoffmann-La Roche Inc. 4-Aminothiazole derivatives
US7423051B2 (en) * 2004-07-15 2008-09-09 Hoffmann-La Roche Inc. 2,6-diaminopyridine derivatives
JP2008512380A (ja) 2004-09-03 2008-04-24 プレキシコン，インコーポレーテッド Ｐｄｅ４ｂ阻害剤
US7241893B2 (en) * 2004-09-17 2007-07-10 Hoffman-La Roche Inc. Thiazolinone 2-substituted quinolines
US7253285B2 (en) * 2004-09-17 2007-08-07 Hoffmann-La Roche Inc. Thiazolinone 4-monosubstituted quinolines
JP2008516903A (ja) 2004-10-14 2008-05-22 エフ．ホフマン−ラ ロシュ アーゲー 抗癌剤としての新規アザインドールチアゾリノン
BRPI0519759A2 (pt) 2004-12-30 2009-03-10 Astex Therapeutics Ltd composiÇÕes farmacÊuticas
EP1836199A1 (en) 2004-12-30 2007-09-26 Astex Therapeutics Limited Thiazole and isothiazole derivatives that modulate the activity of cdk, gsk and aurora kinases
WO2006077428A1 (en) 2005-01-21 2006-07-27 Astex Therapeutics Limited Pharmaceutical compounds
AU2006207321B2 (en) 2005-01-21 2012-09-06 Astex Therapeutics Limited Pharmaceutical compounds
US7304074B2 (en) 2005-04-05 2007-12-04 Hoffmann-La Roche Inc. Substituted 1,5-naphthyridine azolinones
ATE536344T1 (de) 2005-07-04 2011-12-15 High Point Pharmaceuticals Llc Histamine h3 receptor antagonisten
JP4278172B2 (ja) 2005-07-30 2009-06-10 アストラゼネカ アクチボラグ 増殖性疾患の治療において使用するためのイミダゾリル−ピリミジン化合物
US7705009B2 (en) * 2005-11-22 2010-04-27 Hoffman-La Roche Inc. 4-aminopyrimidine-5-thione derivatives
ES2388681T3 (es) 2006-03-28 2012-10-17 High Point Pharmaceuticals, Llc Benzotiazoles con actividad de los receptores de histamina H3
CA2653062A1 (en) 2006-05-23 2007-11-29 Transtech Pharma, Inc. 6- (4-cyclopropylpiperazin-1-yl) -2 ' -methyl- [3, 4 ' ] -bipyridine and its use as a medicament
HRP20120227T1 (hr) 2006-05-29 2012-04-30 High Point Pharmaceuticals 3-(1,3-benzodioksol-5-il)-6-(4-ciklopropilpiperazin-1-il)piridazin, njegove soli i solvati te njegova uporaba kao antagonista histaminskog h3 receptora
BRPI0807626B1 (pt) * 2007-02-13 2022-03-03 Ab Science Processo para a síntese de compostos de 2-aminotiazol como inibidores de quinase
CA2686754C (en) * 2007-05-11 2014-10-28 F. Hoffmann-La Roche Ag Hetarylanilines as modulators for amyloid beta
EP2014656A3 (en) 2007-06-11 2011-08-24 High Point Pharmaceuticals, LLC New heteocyclic h3 antagonists
WO2011159726A2 (en) 2010-06-14 2011-12-22 The Scripps Research Institute Reprogramming of cells to a new fate
EA032429B1 (ru) * 2012-02-02 2019-05-31 Сенекс Биотекнолоджи Инк. Селективные низкомолекулярные ингибиторы cdk8/cdk19 и их применение в качестве агентов для лечения рака
CN102977049A (zh) * 2012-11-26 2013-03-20 盛世泰科生物医药技术(苏州)有限公司 一种2-氨基-4-环丙基-5-羧酸乙酯噻唑的合成方法
CN105579439B (zh) * 2013-05-07 2018-10-19 加州大学评议会 辐射减轻性药物制剂
CN104628627A (zh) * 2014-12-23 2015-05-20 安徽德信佳生物医药有限公司 一种1-boc-4-氨基哌啶的合成方法
CN106854200B (zh) * 2015-12-08 2019-05-21 上海复星星泰医药科技有限公司 色瑞替尼及其中间体的制备方法
WO2018089902A1 (en) * 2016-11-13 2018-05-17 Apogee Biotechnology Corporation Diaminothiazole compounds, compositions and methods of use
US10954216B2 (en) 2016-12-27 2021-03-23 Riken BMP-signal-inhibiting compound
EP4219486A1 (en) * 2017-01-19 2023-08-02 Temple University of the Commonwealth System of Higher Education Novel bridged bicycloalkyl-substituted aminothizoles and their methods of use
CA3090493A1 (en) 2018-02-06 2019-08-15 The Board Of Trustees Of The University Of Illinois Substituted benzothiophene analogs as selective estrogen receptor degraders
CN113321647B (zh) 2018-06-15 2024-08-27 汉达癌症医药责任有限公司 激酶抑制剂的盐类及其组合物
CN109897014A (zh) * 2019-04-17 2019-06-18 成都睿智化学研究有限公司 一种1-（取代苯基）-4-甲基哌嗪的工艺制备方法
CN118453590A (zh) * 2020-09-01 2024-08-09 苏州灵希生物科技有限公司 化合物作为cyp2e1抑制剂的应用
CN114805432A (zh) * 2022-03-03 2022-07-29 西北工业大学 新型可光催化剪切的羧酸保护基及其氨基酸衍生物的制备方法
KR102820358B1 (ko) * 2022-08-30 2025-06-12 한국화학연구원 Mkk3 키나아제 억제 화합물을 함유한 천포창 개선 또는 치료용 조성물
WO2025128616A1 (en) * 2023-12-12 2025-06-19 Genesis Therapeutics, Inc. Compounds for treating cancer

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3530161A (en) 1968-08-19 1970-09-22 Shell Oil Co Aromatic isothiocyanate production
BE792402A (fr) 1971-12-07 1973-06-07 Ciba Geigy Composes heterocycliques azotes et medicaments anthelminthiqueset antimicrobiens qui en contiennent
CH593806A5 (xx) 1974-11-14 1977-12-15 Ciba Geigy Ag
US4086239A (en) 1977-07-01 1978-04-25 Stauffer Chemical Company Thiazole bis-phosphates and phosphonates, intermediates, and insecticidal compositions and methods
US4649146A (en) 1983-01-31 1987-03-10 Fujisawa Pharmaceutical Co., Ltd. Thiazole derivatives and pharmaceutical composition comprising the same
DE3804531A1 (de) 1988-02-13 1989-08-24 Bayer Ag 5-cyano-2,4-diamino-thiazol-derivate
IE68593B1 (en) 1989-12-06 1996-06-26 Sanofi Sa Heterocyclic substituted acylaminothiazoles their preparation and pharmaceutical compositions containing them
US5620963A (en) 1991-10-15 1997-04-15 Isis Pharmaceuticals, Inc. Oligonucleotides for modulating protein kinase C having phosphorothioate linkages of high chiral purity
US5710158A (en) * 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5721237A (en) 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
ES2108120T3 (es) * 1991-05-10 1997-12-16 Rhone Poulenc Rorer Int Compuestos bis arilicos y heteroarilicos mono- y biciclicos que inhiben tirosina quinasa receptora de egf y/o pdgf.
EP0604560B1 (en) 1991-09-20 2004-08-11 Fred Hutchinson Cancer Research Center Human cyclin e
US5262409A (en) 1991-10-11 1993-11-16 Fred Hutchinson Cancer Research Center Binary tumor therapy
US5441880A (en) 1991-11-18 1995-08-15 Cold Spring Harbor Laboratory Human cdc25 genes, encoded products and uses thereof
US5302706A (en) 1991-12-16 1994-04-12 Baylor College Of Medicine Senescent cell derived inhibitors of DNA synthesis
US5596079A (en) 1991-12-16 1997-01-21 Smith; James R. Mimetics of senescent cell derived inhibitors of DNA synthesis
AU4281393A (en) 1992-04-10 1993-11-18 Dana-Farber Cancer Institute, Inc. Activation-state-specific phosphoprotein immunodetection
AU5168393A (en) 1992-09-30 1994-04-26 Yale University Therapeutic and diagnostic methods and compositions based on transducin-like enhancer of split proteins and nucleic acids
US5543291A (en) 1993-01-29 1996-08-06 Dana Farber Cancer Institute Method of detecting carcinoma
ATE406909T1 (de) 1993-05-13 2008-09-15 Poniard Pharmaceuticals Inc Prävention und behandlung von pathologien, die mit einer abnormalen proliferationglatter muskelzellen verbunden sind
US5443962A (en) 1993-06-04 1995-08-22 Mitotix, Inc. Methods of identifying inhibitors of cdc25 phosphatase
US5514571A (en) 1993-08-05 1996-05-07 University Technologies International Inc. Cyclin D1 negative regulatory activity
US5473056A (en) 1993-10-13 1995-12-05 Merck & Co., Inc. E2F-2, a novel mammalian transcription factor
US5532167A (en) 1994-01-07 1996-07-02 Beth Israel Hospital Substrate specificity of protein kinases
US5484710A (en) 1994-01-14 1996-01-16 La Jolla Cancer Research Foundation Method of down-regulating a gene linked to a P-53 responsive element
US5625031A (en) 1994-02-08 1997-04-29 Bristol-Myers Squibb Company Peptide inhibitors of the p33cdk2 and p34cdc2 cell cycle regulatory kinases and human papillomavirus E7 oncoprotein
WO1995025813A1 (en) 1994-03-18 1995-09-28 University Of Utah Research Foundation Germline mutations in the mts gene and method for detecting predisposition to cancer at the mts gene
US5496831A (en) 1994-05-13 1996-03-05 The General Hospital Corporation Inhibition of insulin-induced adiposis
US5631156A (en) 1994-06-21 1997-05-20 The University Of Michigan DNA encoding and 18 KD CDK6 inhibiting protein
US5571523A (en) 1995-03-09 1996-11-05 President And Fellows Of Harvard College Antioxidant-induced apoptosis in vascular smooth muscle cells
US5733920A (en) 1995-10-31 1998-03-31 Mitotix, Inc. Inhibitors of cyclin dependent kinases
US7091346B1 (en) 1995-11-01 2006-08-15 Novartis Ag Purine derivatives and processes for their preparation
US5849733A (en) 1996-05-10 1998-12-15 Bristol-Myers Squibb Co. 2-thio or 2-oxo flavopiridol analogs
TW513418B (en) 1996-07-31 2002-12-11 Otsuka Pharma Co Ltd Thiazole derivatives, their production and use
DZ2285A1 (fr) 1996-08-08 2002-12-25 Smithkline Beecham Corp Inhibiteurs de protéase de la cystéine.
GB9621757D0 (en) 1996-10-18 1996-12-11 Ciba Geigy Ag Phenyl-substituted bicyclic heterocyclyl derivatives and their use
BR9807305A (pt) * 1997-02-05 2000-05-02 Warner Lambert Co Pirido [2,3-d] pirimidinas e 4-aminopirimidinas como inibidores de proliferação celular.
SK5212000A3 (en) * 1997-10-27 2001-04-09 Agouron Pharmaceuticals Inc Ag 4-aminothiazole derivatives, their preparation and their use as inhibitors of cyclin-dependent kinases
UA71971C2 (en) * 1999-06-04 2005-01-17 Agoron Pharmaceuticals Inc Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases

Also Published As

Publication number Publication date
DE69833223D1 (de) 2006-04-06
AP2000001795A0 (en) 2000-06-30
LV12592A (en) 2000-12-20
NO20001955D0 (no) 2000-04-14
ATE332896T1 (de) 2006-08-15
CN1276789A (zh) 2000-12-13
GEP20032896B (en) 2003-02-25
WO1999021845A3 (en) 1999-08-19
DE69833223T2 (de) 2006-09-14
AU738792B2 (en) 2001-09-27
EP1056732B1 (en) 2006-01-11
DE69835241D1 (de) 2006-08-24
AU1366499A (en) 1999-05-17
HUP0004512A2 (hu) 2002-03-28
EA200000464A1 (ru) 2000-12-25
BG64195B1 (bg) 2004-04-30
SI20324A (sl) 2001-02-28
BG104478A (en) 2001-02-28
PL342447A1 (en) 2001-06-04
HRP20000222A2 (en) 2001-02-28
NZ503788A (en) 2002-11-26
DE69835241T2 (de) 2007-05-31
US6569878B1 (en) 2003-05-27
HUP0004512A3 (en) 2003-01-28
OA11352A (en) 2003-12-23
NO20001955L (no) 2000-06-16
AP1445A (en) 2005-07-10
RO119463B1 (ro) 2004-11-30
EP1056732A2 (en) 2000-12-06
YU22400A (sh) 2003-08-29
UA66810C2 (uk) 2004-06-15
BR9815200A (pt) 2001-10-16
US20030220326A1 (en) 2003-11-27
WO1999021845A2 (en) 1999-05-06
LV12592B (en) 2001-07-20
ATE315553T1 (de) 2006-02-15
EA003527B1 (ru) 2003-06-26
IS5462A (is) 2000-04-19
ID24372A (id) 2000-07-13
IL135574A0 (en) 2001-05-20
CA2306082A1 (en) 1999-05-06
TR200001081T2 (tr) 2000-10-23
ES2256968T3 (es) 2006-07-16
SK5212000A3 (en) 2001-04-09
KR20010082501A (ko) 2001-08-30
LT2000033A (en) 2001-06-25
ES2267873T3 (es) 2007-03-16
JP2004500304A (ja) 2004-01-08
CN1158269C (zh) 2004-07-21
LT4855B (lt) 2001-11-26

Similar Documents

Publication Publication Date Title
EE200000289A (et) Asendatud 4-amino-tiasool-2-üüli ühendid kui tsükliinisõltuvusega kinaaside inhibiitorid
DK1042307T3 (da) Aminothiazolinhibitorer af cyclinafhængige kinaser
ID22982A (id) PIRAZOL-PIRAZOL TERSUBSTITUSI SEBAGAI INHIBITOR KINASE p38
EE04616B1 (et) Bitsüklilised heteroaromaatsed ühendid kui valgu türosiini kinaasi inhibiitorid
NO20005673D0 (no) Heterocykliske inhibitorer av P38
DK1183033T3 (da) Pyrrolotriazininhibitorer af kinaser
NO992960L (no) Substituerte nitrogen-inneholdende heterocykliske forbindelser som inhibitorer for p38 protein-kinase
DK1114051T3 (da) Inhibitorer for p38
EE200200140A (et) Pteridinoonid kui kinaasi inhibiitorid
NO20022864L (no) Aminotiazol inhibitorer av syklin uavhengig kinase
NO20006483L (no) Forbindelser av ustabile dipeptidyl peptidase IV-inhibitorer
EE9800351A (et) Asendatud benseensulfoonamiidi derivaadid kui COX-2 inhibiitorite eelravimid
ATE251160T1 (de) Purin-derivative inhibitoren der tyrosi-protein kinase syk
FI963228A7 (fi) Substituoituja bifenyylijohdannaisia fosfodiesteraasi-inhibiittoreina
PT1049695E (pt) Imidazotriazinonas 2-fenil substituidas enquanto inibidores de fosfodiesterase
EE200300227A (et) P38 kinaasiga seotud haigusseisundite ravimeetodid ja kinaasi inhibiitoritena kasulikud pürrolotriasiiniühendid
DE69831950D1 (de) Inhibitoren des hitzeschock-faktors
PL339186A1 (en) Derivatives of pyrrolopyrrolone as inhibitors of neutrophilic elastase
GB9706652D0 (en) Inhibitors of FPT as anti-inflammatories
PT1175417E (pt) Compostos substituidos de benzolactamas